MedTrace Logo

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

NCT02664883 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2026-04-02

No results posted yet for this study

Summary

This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to therapy, detect the presence of occult spreading of disease, and identify early return of disease.

Conditions

  • Healthy Subject
  • Metastatic Renal Cell Cancer
  • Recurrent Renal Cell Carcinoma
  • Stage I Renal Cell Cancer
  • Stage II Renal Cell Cancer
  • Stage III Renal Cell Cancer

Interventions

PROCEDURE

Computed Tomography

Correlative studies

OTHER

Cytology Specimen Collection Procedure

Undergo collection of blood and urine samples

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Jacek Pinski, MD · University of Southern California

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-08
Primary Completion
2022-04-13
Completion
2026-10-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02664883 on ClinicalTrials.gov